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Localization of decay accelerating factor in normal and diseased
kidneys; Decay accelerating factor (DAF) is a cell membrane associated
glycoprotein that inhibits C3 activation. In the present study we
evaluated the presence of DAF in normal (N = 15)and diseased human
kidneys (N = 76). Sections of frozen tissue were stained for DAF by
immunoperoxidase, utilizing three mouse monoclonal anti-DAF anti-
bodies. In normal kidneys, DAF was localized in the glomerular
vascular pole, apparently in the juxtaglomerular apparatus (JGA). All
other structures were negative for DAF. By contrast, in diseased
kidneys, two types of abnormalities were detected. First, JGA-DAF
was significantly decreased and this abnormality correlated with the
pathologic diagnosis and with the presence of C3, 1gM and/or fibrinogen
in the glomeruli. Second, DAF was present in the glomerular mesan-
glum (67%), renal interstitium (68%) and/or blood vessels (38%). The
presence of DAF in the mesangium and interstitium of the kidney
correlated with each other and correlated with CIq and C3 deposition in
the glomerulus. Finally, vascular DAF was significantly more common
in patients with electron dense deposits in the glomeruli, In summary,
DAF is present in the normal kidney and is located exclusively in the
glomerular vascular pole. In diseased kidneys, DAF tends to be lost
from the JGA but is often present in glomerular mesangium, interstitium
and blood vessels. This pattern is specially prominent in patients
demonstrating complement deposition in the glomerulus. We speculate
that kidney DAF may play a role in protecting the kidney against the
products of complement activation.
Decay accierating factor (DAF), is a glycoprotein that is
present in the membrane of all circulating human blood cells [I,
2] and in human endothelial and epithelial cells in culture [3, 4].
The function of DAF is to limit complement activation on cell
surfaces thereby inhibiting cell lysis. DAF inhibits the forma-
tion and accelerates the decay of both classic and alternative
pathway C3 convertases, thus limiting C3 activation [1, 2, 5].
These effects also result in inhibition of terminal pathway
complement activation (C5 to C9) because C3b is an integral
part of the CS convertases. The importance of DAF in cell
protection is demonstrated in paroxysmal nocturnal hemoglo-
binuria (PNH). The erythrocytes of some PNH patients lack
DAF and demonstrate unusual sensitivity to complement me-
diated hemolysis [6, 7]. In addition, if DAF is restored in these
erythrocytes, the erythrocytes are no longer inordinately sen-
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sitive to complement mediated lysis [8]. We postulate that DAF
could play a similar protective role in the kidney. The present
study was undertaken as the initial step to test that hypothesis.
Methods
Tissues
Specimens from 15 normal human kidneys and 76 pathologic
human kidneys were studied. Normal human kidneys were
obtained from patients undergoing unilateral nephrectomies for
removal of renal tumors. The renal tissue was immersed in
precooled isopenthane (Sigma Chemical Co., St. Louis, Mis-
souri, USA) and frozen at —70°C. Cryostat sections of frozen
tissue were placed on glass slides, fixed with acetone and air
dried overnight. In some cases tissues were fixed with other
fixatives. Pathologic kidney specimens were obtained by per-
cutaneous or surgical biopsy in patients with a variety of renal
diseases. These pathologic specimens were collected prospec-
tively and all biopsies performed during the study period were
included.
DAF staining
Tissue sections were stained for DAF by the following
method: First, endogenous tissue biotin and avidin were
blocked by incubation with blocking reagent (Blocking kit,
Vector Laboratories, Burlingame, California, USA). Subse-
quently, tissue sections were incubated, at room temperature
for 30 minutes, with one of three mouse monoclonal anti-DAF
antibodies (IA 10, 11H6 and VIIIA7) [2, 4]. Normal kidneys were
stained with all three antibodies while pathologic specimens
were stained with the antibody lAb. These monocbonal anti-
DAF antibodies were from Dr. V. Nussenzweig (New York
University, NY). After washing, tissues sections were incu-
bated sequentially with the following reagents: biotin-labeled
horse antimouse IgG (Vector) (room temperature for 30 mm),
avidin-biotin-peroxidase complexes (ABC reagent, Vector;
room temperature for 30 mm) and peroxidase substrate (3-
amino-9-ethylcarbazole, Sigma; room temperature for 5 mm).
Prior to mounting, tissues were counterstained with hematox-
ylin. In all cases, control tissue sections were incubated with all
of the above mentioned reagents with the exception of anti-
DAF antibodies. In addition, tissue sections incubated with an
irrelevant IgG I mouse monocbonal anti-DNP antibody instead
of anti-DAF antibodies, were negative.
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Fig. 1. Localization of DAF in normal human
kidney. DAF is present exclusively in the
vascular pole of the kidney in the JGA region
(original magnification x 100).
Peroxidase stained tissues were examined without prior
knowledge of diagnosis. Only those tissues containing at least
five glomeruli per section were included in the study. Sclerotic
glomeruli were not counted. Except in the case of surgical
kidney biopsies (where the amount of tissue available was
greater) a minimum of three sections per specimen were stained
for DAF. Each tissue section was read separately and the data
were reported as follows. First, the total number of glomeruli in
the section and the number of glomeruli demonstrating a DAF
positive area in the vascular pole were counted and the results
were reported as the percent DAF positive glomeruli. Second,
the presence of DAF in areas other than the vascular pole of the
glomerulus was noted.
As part of the clinical evaluation of kidney biopsies, all
pathologic specimens were examined by light, electron and
immunofluorescence microscopy. The latter included staining
for IgG, 1gM, IgA, Clq, C3 and fibrinogen by routine laboratory
methods utilizing FITC labeled monospecific antibodies (Beh-
ring diagnostics, St. Diego, California, USA). Light, electron
and immunofluorescence microscopy studies were performed
by the Pathology Department, Ohio State University and the
interpretation of those studies was performed independently of
the present study.
Analysis of the data
Analysis of variance (ANOVA), Student's t-test, chi-square,
linear regression (least squares) and Wilcoxon's test were used
for analysis of the data.
DAF distribution in normal kidneys
DAF was present in the vascular pole of glomeruli, in the
region of the juxtaglomerular apparatus (JGA), in all normal
kidney specimens (Fig. I). The presence of DAF in that location
was demonstrated independently with all three monoclonal
anti-DAF antibodies (jAb, 11H6 and VHIA7). In normal kid-
neys, we did not demonstrate DAF staining in cells of the
macula densa (Fig. 2), vascular endothelium, tubular epithelial
cells or mesangial cells. In occasional specimens, focal DAF
staining was noted in connective tissues of the interstitium and
the renal capsule.
The sections of normal kidney tissue evaluated in the present
study (I to 5 sections per specimen) contained a mean of 26
glomeruli per section (range 7 to 70). In a given tissue section,
64 9% of glomeruli (mean SD) demonstrated a JGA-DAF
positive area. This result may imply an uneven distribution of
DAF among different glomeruli or may represent the fact that
not all glomeruli were sectioned through the vascular pole,
where DAF is normally present. The following observations
favor the latter explanation. The percent of JGA-DAF positive
glomeruli in the outer versus the inner half of the renal cortex
was not significantly different (N = 9) (68 13% and 63 11%,
respectively), In addition, staining of the same gbomeruli
present in serial sections of normal renal tissue (Table 1)
demonstrated that glomeruli negative for DAF in one section
were positive for DAF in other sections.
Results
4-, I/
S fi
Glomeruli
#
Section #
1 2 3 4 5
1 — — + + +
2 + + + + No
3 — + — — No"
4 — — — + +
5 + + + + +
6 — — — + +
7 + + + — —
8 + + + + —
9 + + — — —
10 — — -I- + +
11 — — — — —
12 + + + + —
13 + + + + —
14 — — + N No
The antigenicity of DAF in normal kidneys was altered by the
method of tissue fixation. Thus, JGA-DAF was detectable in
kidneys fixed with acetone, 35 to 70% ethanol or 50 to 90%
methanol but not in tissues fixed with 10% formaldehyde, 4%
paraformaldehyde, glutaraldehyde (0.05 to 1%) or 2% PLP (2%
paraformaldehyde in lysine phosphate buffer and sodium
metaperiodate). In addition, DAF was not detectable in glomer-
uli of kidneys obtained from autopsies (N = 2), suggesting that
DAF is sensitive to autolysis.
Fig. 2. Higher power view of DAF localization in
the JGA demonstrating lack of staining in
macu/a densa cells. CL: capillary lumen; MC:
macula densa; JGA: juxtaglomerular apparatus
(original magnification 160x).
DAF distribution in diseased kidneys
Compared to the distribution of DAF in the normal kidney,
diseased kidney specimens demonstrated two types of abnor-
malities, First, there were significant changes in the percent of
glomeruli demonstrating DAF in the JGA and second, in some
pathologic specimens, DAF was present in the glomerular
mesangium, renal interstitium and blood vessels. We will con-
sider these two findings separately.
JGA-DAF in diseased kidneys. There was a statistically
significant difference between the percent JGA-DAF positive
glomeruli in normal kidneys and in diseased kidneys (64 9%
and 48 20%, respectively, P = 0.001 by Wilcoxon nonpara-
metric test; Fig. 3). In addition, in pathologic specimens, the
percent of JGA-DAF positive glomeruli was significantly dif-
ferent among specimens with different pathologic diagnosis
(Table 2). Thus, patients with systemic lupus erythematosus
(SLE), rapidly progressive glomerulonephritis (RPGN), hemo-
lytic uremic syndrome (HUS) and interstitial nephritis (IN)
demonstrated significantly lower percent JGA-DAF-positive
glomeruli than normal. The group of SLE patients included
patients with mesangial (N 5), focal proliferative (N 1) or
diffuse proliferative (N = 3) glomerulonephritis. The group of
patients with RPGN included patients with linear immunofluo-
rescence (N = 2), granular immunofluorescence (N 3) or
negative immunofluorescence (N 5) in the glomeruli. Of
importance, differences in percent JGA-DAF positive glomeruli
among patients with different diagnoses were not due to differ-
ences in the total number of glomeruli per section. Thus, there
was no statistically significant correlation between the total
number of glomeruli per section and the percent of JGA-DAF
102 Cosio et a!: Kidney decay-accelerating factor
Table 1. JGA-DAF in 5 sequential cryostat sections of a normal
human kidney specimen
Each glomeruli in the first section was given an arbitrary number and
identified in sequential sections by its location in the section.
a The specific glomeruli was not seen in that section.
MD-
iJGA
CL
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Table 2. Percent JGA-DAF positive glomeruli in normal and in
diseased human kidneys in association with pathologic diagnosis
JGA-
DAF #of
positive Glomeruli
glomeruli per
Diagnosis N % section
Normal 15 64 9 26 l6
IgA nephropathy 8 65 16 14 4
MN 10 57±12 14±7
Mesangial 7 57 12 12 8
FGS 9 53±15 14±8
MPGN 6 52±15 18±4
HUS 4 19±6
IN 4 14±7
SLE 9 14±6
RPGN 10 33 21b 19 6
Miscellaneous 8 49 17 15 7
DM (2) 50,55 20,6
Scleroderma (1) 9 Il
ATN (1) 61 18
Wegener's (1) 60 10
Familial (1) 50 8
nephropathy
MCNS (1) 47 18
Nephrosclerosis (1) 62 26
positive glomeruli in that section (r = 0.14). Furthermore, there
were no statistically significant differences in the total number
of glomeruli per section among the various disease categories
(Table 2).
The percent JGA-DAF positive glomeruli in a given specimen
was considered to be abnormal if it was greater than 2 standard
deviations below the mean for normal kidneys. By this criteria,
33 of the 76 pathologic specimens (43%) demonstrated signifi-
cantly decreased percent JGA-DAF positive glomeruli (Fig. 3).
The association between abnormal JGA-DAF and parameters
obtained by light, immunofluorescence and electron micros-
copy (EM; Table 3) was analyzed statistically. EM was not
performed in normal tissues and thus, those tissues were not
included in the analysis of the association between decreased
Parameter Value
% of Patients
with decreased
JGA-DAF Chi-square
IgG —
+
35
38 NSb
1gM —
+
18
51 P<0.002
IgA —
+
35
39 NS
Clq —
+
28
44 NS
C3 —
+
19
47 P<0.007
Fibrinogen
EM deposits
—
+
No
Yes
24
68
31
43
P<0.001
NS
JGA-DAF and EM findings. Patients demonstrating 1gM, C3 or
fibrinogen in glomeruli had a significantly higher incidence of
decreased JGA-DAF than patients who did not demonstrate
these findings. By contrast, there were no significant differences
in the incidence of decreased JGA-DAF and the presence of
IgG, IgA, Clq or the presence of electron dense deposits in the
glomeruli (Table 3).
When all pathologic specimens were considered, the percent
of JGA-DAF positive glomeruli did not demonstrate a linear
correlation with the degree of proteinuria nor with the serum
creatinine (Fig. 4). However, the percent JGA-DAF positive
glomeruli was significantly lower in patients with elevated
serum creatinine (>1.5 mg/dl; N = 42, mean 41.2 4.5 SE) than
in patients with normal serum creatinine (l.5 mgldl; N = 28,
mean 59.5 32.2 SE; P < 0.01 by t-test).
DAF in mesangium, interstitium and blood vessels of dis-
eased kidneys. Mesangial DAF was demonstrated in 51 of 76
pathologic specimens (67%; Fig. 5A,B). Table 4 demonstrates
the pathologic diagnosis in patients with mesangial DAF. The
presence of DAF in the glomerular mesangium was significantly
more common in patients with glomerular 1gM, Clq, C3,
glomerular crescents and/or electron dense deposits than in
patients without these pathologic findings (Table 5). In addition,
the presence of DAF in the mesangium was significantly more
common in specimens demonstrating interstitial DAF but not in
specimens with vascular DAF or with decreased percent JGA-
DAF. SLE patients demonstrated the lowest incidence of
positive mesangial DAF (33%, Table 4) despite the fact that all
those patients demonstrated immunoglobulins and complement
deposition in the glomeruli.
DAF was present in the interstitium of 52 of 76 pathologic
specimens evaluated (68%). In most cases DAF staining was
focal and appeared to be localized to areas of expanded
interstitium (Fig. 5C). In addition, in four patients (3 with
RPGN and I with IN) DAF positive cells were present in areas
of intense interstitial infiltration with inflammatory cells (Fig.
SC). Table 4 demonstrates the pathologic diagnosis in patients
0-
8
Table 3. Analysis of the association between decreased percent JGA-
DAF positive glomeruli and deposition of immunoglobulins,
complement, fibrinogen or the presence of electron dense deposits
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Fig. 3. Percent JGA-DAF positive glomeruli in normal kidneys (N =
15) and pathologic kidney specimens (N = 76). Horizontal lines show
means standard deviation of the mean.
a For example, percent of patients with negative IgG and decreased
JGA-DAF
b Statistically not significant
N, Number of patients.
a Values represent mean I standard deviation.
b p < 0.0001 compared to normal analyzed by ANOVA.
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>
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with interstitial DAF. Finally, interstitial DAF was significantly
more common in specimens demonstrating Clq, C3 and/or
electron dense deposits in the glomeruli (Table 5).
DAF was detectable in blood vessels in 29 of 76 pathologic
specimens (38%). In 27 of the 29 specimens the vascular media
was positive for DAF. In two specimens (1 HUS and I MPGN),
endothelial DAF staining was demonstrated (Fig. SD, E). Table
4 demonstrates the pathologic diagnosis in patients with DAF in
blood vessels. Vascular DAF was present more frequently in
patients with glomerular electron-dense deposits (Table 5).
Fibroepithelial crescents were present in 11 patients. In
seven of these patients the crescents were positive for DAF
(Fig. SF).
Discussion
This study demonstrates that DAF is present in the normal
human kidney. DAF is localized in the vascular pole of glomer-
uli, apparently in the JGA. This localization of DAF was
demonstrated with the use of three monoclonal anti-DAF
antibodies that recognize three different epitopes of erythrocyte
DAF [2]. Thus, it can be inferred that the molecule identified in
the glomerular vascular pole is DAF and that renal DAF and
erythrocyte DAF are antigenically similar.
The renal localization of DAF that we have demonstrated is
in disagreement with the report of Medof et al [4]. They found
DAF in renal tubular epithelial cells but not in the JGA. It
seems likely that the reason for the discrepancy between the
studies resides in the source of renal tissues used. Thus, the
present findings are based on examination of kidney biopsy
tissue frozen soon after retrieval. By contrast, Dr. Medof
studied kidneys obtained at autopsy. When we studied autopsy
renal tissue, we could not identify DAF in the JGA. These
observations emphasize the importance of obtaining fresh tis-
sues for the study of renal DAF.
The biological significance of DAF in the kidney is not clear.
Based on available evidence we hypothesize that the JGA may
be the site of origin of urinary DAF. Alternatively, it may be
postulated that urine DAF represents filtration of serum DAF.
We favor the hypothesis that DAF is synthesized in the kidney
for the following reasons: DAF has a molecular weight of 70 kd.
Thus, DAF should be excluded from filtration by the normal
glomerular barrier. In addition, urinary DAF has unique molec-
ular and functional characteristics. Specifically, the erythrocyte
DAF molecule contains a glycolipid portion that permits its
incorporation into other cell membranes [5, 8, 9]. By contrast,
the urine DAF molecule lacks this glycolipid portion and does
not have the capacity to incorporate into cell membranes. By
this molecular characteristic, urinary DAF inhibits complement
activation in solution [4]. These molecular and functional dif-
ferences indicate that it would be unlikely that DAF in kidney
tissue represents the accumulation of DAF released from cir-
culating cells.
JGA-DAF might also serve as a regulator of complement
activation in the kidney. This is suggested by the distribution of
DAF in pathologic specimens. That is, in diseased kidneys,
JGA-DAF was significantly decreased and that decrease was
significantly more common in specimens demonstrating C3 in
the glomeruli. We postulate that complement activation in the
glomerulus may result in decreased JGA-DAF synthesis or
DAF consumption or release of DAF stored in the JGA.
However, not all patients demonstrating complement deposi-
tion in the glomerulus had decreased JGA-DAF. Thus, other
factors may also affect JGA-DAF. Those factors might be: 1)
disease process itself because decreased JGA-DAF was more
common in patients with particular diagnosis; 2) the presence of
fibrinogen in the kidney because decreased JGA-DAF was seen
more often when fibrinogen was present in the glomerulus. To
our knowledge, there is no evidence that DAF has a role in
coagulation although, the coagulation cascade is frequently
activated during complement activation [10]. It is possible that
the presence of fibrinogen simply reflects the magnitude of
complement activation and/or the severity of the inflammatory
process. 3) Severity of renal disease may be a factor because
the percent JGA-DAF positive glomeruli was significantly
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Fig. 4. Relationship between percent JGA-
DAF positive glomeruli and serum creatinine
concentration. The vertical division in the
graph indicates the upper limit of normal for
serum creatinine (1.5 mg/dl). The horizontal
0 1 2 3 4 5 6 7 8 9 10 12 division in the graph indicates the lower limit
of normal (mean 2 SD) for percent JGA-
Serum creatinine, mg/dI DAF positive glomeruli.
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Fig. 5. A. Mesangial DAF staining in a patient with membranous nephropathv. B. Mesangial DAF in a patient with Goodpasture's syndrome.
Note the DAF negative fibroepithelial crescent (arrow). C. Interstitial DAF in a patient with interstitial nephritis. Note DAF positive cells in the
renal interstitium (arrow). D. Positive vascular DAF in a patient with scleroderma. E. Endothelial DAF staining in a patient with HUS. Note DAF
positive cells in the mesangium (arrow). F. DAF in fibroepithelial crescents in a patient with RPGN (arrow).
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Table 4. Pathologic diagnosis in patients demonstrating mesangial,
interstitial and/or vascular DAF
Diagnosis (N)
Mesangial
DAF
Interstitial
DAF
Vascular
DAF
N (%)
IgA nephropathy (8) 4 (50) 6 (75) 3 (38)
MN (10) 6 (60) 8 (80) 4 (40)
Mesangial (7) 6 (80) 6 (86) 4 (57)
FGS (9) 6 (67) 8 (89) 2 (22)
MPGN (7) 6 (86) 4 (57) 4 (57)
HUS (4) 4 (100) 2 (50) 1 (25)
IN (4) 2 (50) 4 (100) 2 (50)
SLE (9) 3 (33) 4 (44) 3 (33)
RPGN (10) 9 (50) 7 (70) 1 (10)
Miscellaneous
DM(2) 1 1 2
Scleroderma (1) 1 1 I
ATN(1) 0 0 0
Wegener's (1) 1 1 1
Familial 0 0 0
nephropathy (1)
MCNS(I) 1 0 0
Nephrosclerosis (I) 0 0 I
Total (76) 51 52 29
N = Number of patients
Table S. Analysis of the association between mesangial, interstitial
and/or vascular DAF and other pathologic findings
Parameter Value
Mesangial
DAF
Interstitial
DAF
Vascular
DAF
%
IgG
+
sia
60
51
70
25
40
1gM —
+
37
69
51
65
31
32
IgA —
+
54
61
56
70
28
43
Clq — 466b
46
73d
26
38
C3 —
+
32
68
39
70
19
38
Fibrinogen
EM deposits
—
+
No
Yes
50
72
69
67
58
64
48
71C
30
36
23
43b
Crescents No
Yes
51
91b
59
64
34
18
Interstitial — 38 — —
DAF + 69C
Vascular — 52 50 —
DAF + 66 79 —
% JGA-DAF Normal
Decreased
56
56
55
61
33
26
Compared to — (or no) values (chi-square):
a For example, percent of patients with — IgG and mesangial DAF.b P < 0.05
P < 0.025d P < 0.01
P < 0.005
lower in patients with abnormal kidney function. Finally, it
might be suggested that the antigenicity of DAF is changed by
disease. If that was the case, decreased JGA-DAF, assessed by
immuno-peroxidase stain, might represent an antigenic change
and not a quantitative change. We believe this explanation is
unlikely because most specimens demonstrating decreased
JGA-DAF demonstrated increased DAF in other locations.
In pathologic specimens, DAF was demonstrated in the
glomerular mesangium, renal interstitium and blood vessels.
The presence of DAF in those locations may be the result of in
situ synthesis by kidney cells or may be due to DAF synthesis
by infiltrating inflammatory cells. The present findings favor in
situ synthesis for the following reasons: 1) mesangial and
interstitial DAF staining was diffuse and not localized to spe-
cific cells; 2) mesangial DAF was present in diseases, such as
HUS and MN, where glomerular infiltration with inflammatory
cells is not a conspicuous feature; 3) in those patients demon-
strating DAF positive interstitial inflammatory cells, DAF stain-
ing was localized to individual cells and was not diffuse. Since
DAF is an inhibitor of complement activation, one may expect
DAF changes to be associated with evidence of complement
deposition in tissues. Indeed, both mesangial and interstitial
DAF were associated with the presence of Clq and/or C3 in the
glomeruli. The presence of DAF in tissues negative for Clq and
C3 may be due to the fact that Cl q and C3 stains underestimate
the occurrence of complement activation in tissues. Thus,
previous studies have demonstrated the presence of the mem-
brane attack complex of complement (MAC) in a variety of
renal locations, essentially under all pathologic circumstances
and even in some normal tissues [111.
The present studies suggest that DAF may play a role in the
control of complement activation in the kidney. Furthermore,
these results suggest that kidney cells may synthesize or
express DAF under certain pathologic conditions. DAF may be
an important local inhibitor of complement activation in the
kidney. As such, DAF may be a determinant of the extent of
kidney damage that occurs during pathologic processes.
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